Lantern Pharma publishes investor presentation on AI-driven oncology drug development platform, pipeline programs - LTRN News | RalliesLantern Pharma publishes investor presentation on AI-driven oncology drug development platform, pipeline programs
L
LTRN• Investor presentation highlights RADR platform and pipeline
- Lantern Pharma highlighted its RADR AI platform, targeting a 70% cut in early-stage development timelines and an 80% reduction in costs.
- RADR was cited as predicting and stratifying real-world trial patients with 88% accuracy, supporting biomarker-driven enrollment strategies.
- Lead program LP-300 is in a Phase 2 trial in never-smoker NSCLC, with preliminary data showing an 86% clinical benefit rate.
- LP-300 showed a median progression-free survival of 8.4 months in an EGFR exon 21 L858R cohort; disease control rate was 87%.
- Pipeline update included LP-284 in Phase 1 for recurrent lymphomas and soft tissue sarcomas; LP-184 advanced solid-tumor trials planned.
SPY
•
